TCD |
|
| |
Rimed's Transcranial Doppler (TCD) devices are easy-to-apply non-invasive systems used for measuring blood flow velocities in the brain's basal arteries.
|
|
| |
Digi-LiteTM is based on the latest chip technology and the most advanced software platform – Microsoft .NET – Digi-Lite™ is uniquely an all-digital Transcranial Doppler (TCD) system that offers the medical professional a range of important advantages:
64 gates per probe, that’s double what other systems offer
Enhanced M-Mode for quicker and more accurate detection of blood flow and vessel localization, and improved emboli detection capabilities
Highest accuracy and reliability: most sensitive Doppler on the market ,highest signal-to-noise (S/N) ratio
Full Doppler replay, storage, and analysis of spectrum + sound + M-Mode
Advanced, user-friendly features: enhanced analysis options, full replay, dynamic display of up to 8 spectrums, powerful database with advanced storage and sophisticated search functions
The Most Advanced Patient Report Generator: Flexible and customizable to meet individual needs.
Very user friendly: In the RIMED tradition of user-friendly medical devices, Digi-Lite™, like its predecessors, is designed to easily accommodate the individual needs of the user – and to do so quickly and easily.
Unique to Rimed's Transcranial Doppler is the option for the Digi-Lite™IP (Imaging Probe) addon. The Digi-Lite™IP color ultrasound module connects to the Digi-Lite via the USB port. This combination offers a complete solution to a modern Neurosonology lab as it performs diagnosis of both the Intracranial arteries and the Carotid arteries in the neck.
Transcranial Doppler (TCD) - clinical applications
Routine Transcranial Doppler (TCD) ultrasound examination of the intracranial arteries was demonstrated to be possible in 1982. The American Academy of Neurology technology assessment report published in 1990 stated that TCD has established value in the assessment of patients with intracranial stenosis, collaterals, subarachnoid haemorrhage, and brain death. In 1999, a panel of international experts critically reviewed the literature published up to 1998 and ranked the specific clinical applications of TCD based on the strength and quality of published evidence. The Board of Directors of the American Society of Neuroimaging and the Neurosonology Research Group of the World Federation of Neurology has approved this document.
|
|
|
